The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict STAAR Surgical's revenues will increase 7.2% and EPS will contract 0.0%.
The average estimate for revenue is $17.6 million. On the bottom line, the average EPS estimate is $0.03.
Last quarter, STAAR Surgical chalked up revenue of $15.9 million. GAAP reported sales were 3.9% higher than the prior-year quarter's $15.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.04. GAAP EPS of $0.00 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 70.4%, 190 basis points better than the prior-year quarter. Operating margin was 4.0%, 80 basis points worse than the prior-year quarter. Net margin was -0.6%, 110 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $64.9 million. The average EPS estimate is $0.09.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 80 members out of 88 rating the stock outperform, and eight members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give STAAR Surgical a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is outperform, with an average price target of $9.65.
Is STAAR Surgical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add STAAR Surgical to My Watchlist.